James Ray, MD
Family Medicine · Swainsboro, GANPI 1679523419
Payments from drug & device makers
Across 106 payments — averaging $15.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$337
- Novo Nordisk$153
- Lilly USA, LLC$145
- AstraZeneca$133
- Novartis$101
- Daiichi Sankyo Inc.$79
- plus $736 from 18 others
What the payments were for
- Food & beverage$1,685100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 22 | $337 |
| Novo Nordisk | 9 | $153 |
| Lilly USA, LLC | 9 | $145 |
| AstraZeneca | 9 | $133 |
| Novartis | 6 | $101 |
| Daiichi Sankyo Inc. | 5 | $79 |
| GSK | 5 | $77 |
| Pfizer | 5 | $75 |
| Sanofi-aventis U.S. LLC | 4 | $71 |
| Merck | 4 | $68 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $56 |
| Biogen | 3 | $55 |
| Kowa Pharmaceuticals America, Inc. | 4 | $55 |
| Johnson & Johnson | 4 | $51 |
| Vanda Pharmaceuticals Inc. | 3 | $50 |
| Boehringer Ingelheim | 2 | $37 |
| Alkermes, Inc. | 2 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Indivior Inc. | 1 | $18 |
| Exact Sciences | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Amgen | 1 | $13 |
| Eisai Inc. | 1 | $13 |
| Shire North American Group Inc | 1 | $12 |
How this compares
$1,685 in reported general payments places this provider in the 65th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 324 | $102,584 |
| JardianceEmpagliflozin | 219 | $60,699 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $32,837 |
| TrulicityDulaglutide | 28 | $28,897 |
| LinzessLinaclotide | 42 | $26,289 |
| GocovriAmantadine Hcl | 14 | $24,117 |
| RybelsusSemaglutide | 18 | $17,287 |
| OzempicSemaglutide | 13 | $15,991 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 574 | $14,099 |
| JanuviaSitagliptin Phosphate | 25 | $12,569 |
| Divalproex Sodium | 234 | $10,881 |
| Potassium Chloride | 608 | $10,742 |
| FarxigaDapagliflozin Propanediol | 29 | $10,447 |
| MyrbetriqMirabegron | 31 | $9,452 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $8,464 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $75 | $102,584324 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $37 | $73,857245 claims |
| Novo NordiskRybelsus, Ozempic | $153 | $33,27831 claims |
| GSKTrelegy Ellipta | $77 | $32,83746 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta | $133 | $30,97279 claims |
| Lilly USA, LLCTrulicity | $145 | $28,89728 claims |
| AbbVieLinzess | $337 | $26,28942 claims |
| MerckJanuvia | $68 | $12,56925 claims |
| Johnson & JohnsonXarelto | $51 | $4,47118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Swainsboro
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.